Park, A.; Yang, Y.; Lee, Y.; Kim, M.S.; Park, Y.-J.; Jung, H.; Kim, T.-D.; Lee, H.G.; Choi, I.; Yoon, S.R.
Indoleamine-2,3-Dioxygenase in Thyroid Cancer Cells Suppresses Natural Killer Cell Function by Inhibiting NKG2D and NKp46 Expression via STAT Signaling Pathways. J. Clin. Med. 2019, 8, 842.
https://doi.org/10.3390/jcm8060842
AMA Style
Park A, Yang Y, Lee Y, Kim MS, Park Y-J, Jung H, Kim T-D, Lee HG, Choi I, Yoon SR.
Indoleamine-2,3-Dioxygenase in Thyroid Cancer Cells Suppresses Natural Killer Cell Function by Inhibiting NKG2D and NKp46 Expression via STAT Signaling Pathways. Journal of Clinical Medicine. 2019; 8(6):842.
https://doi.org/10.3390/jcm8060842
Chicago/Turabian Style
Park, Arum, Yunjeong Yang, Yunhee Lee, Mi Sun Kim, Young-Jun Park, Haiyoung Jung, Tae-Don Kim, Hee Gu Lee, Inpyo Choi, and Suk Ran Yoon.
2019. "Indoleamine-2,3-Dioxygenase in Thyroid Cancer Cells Suppresses Natural Killer Cell Function by Inhibiting NKG2D and NKp46 Expression via STAT Signaling Pathways" Journal of Clinical Medicine 8, no. 6: 842.
https://doi.org/10.3390/jcm8060842
APA Style
Park, A., Yang, Y., Lee, Y., Kim, M. S., Park, Y.-J., Jung, H., Kim, T.-D., Lee, H. G., Choi, I., & Yoon, S. R.
(2019). Indoleamine-2,3-Dioxygenase in Thyroid Cancer Cells Suppresses Natural Killer Cell Function by Inhibiting NKG2D and NKp46 Expression via STAT Signaling Pathways. Journal of Clinical Medicine, 8(6), 842.
https://doi.org/10.3390/jcm8060842